Somatostatin, growth hormone-releasing hormone, galanin and their hypothalamic messenger ribonucleic acids in the regulation of sleep in rats by Toppila, Jussi
SOMATOSTATIN, GROWTH HORMONE-RELEASING
HORMONE, GALANIN AND THEIR HYPOTHALAMIC
MESSENGER RIBONUCLEIC ACIDS IN THE REGULATION
OF SLEEP IN RATS
Jussi Toppila
HELSINKI 1999
SOMATOSTATIN, GROWTH HORMONE-RELEASING
HORMONE, GALANIN AND THEIR HYPOTHALAMIC
MESSENGER RIBONUCLEIC ACIDS IN THE REGULATION
OF SLEEP IN RATS
Jussi Toppila
Institute of Biomedicine, Department of Physiology, University of Helsinki, Finland
Academic Dissertation
To be publicly discussed, by the permission of the Medical Faculty of the University of
Helsinki, in the auditorium of the Institute of Biomedicine, Department of Physiology
(Siltavuorenpenger 20 J) on November 5th 1999, at 12 noon.
HELSINKI 1999
Supervised by
Professor Dag Stenberg M.D. Ph.D., University of Helsinki, Finland
Docent Tarja Porkka-Heiskanen M.D. Ph.D., University of Helsinki, Finland
Reviewed by
Professor Juhani Leppäluoto M.D. Ph.D., University of Oulu, Finland
Professor Leena Rechardt M.D. Ph.D., University of Helsinki, Finland
Opponent
Docent Olli Polo M.D. Ph.D., University of Turku, Finland
ISBN 951-45-8724-3 (PDF version)
H e l s i n g i n  y l i o p i s t o n  v e r k k o j u l k a i s u t , Helsinki 1999
TABLE OF CONTENTS
ABBREVIATIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
LIST OF ORIGINAL PUBLICATIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
INTRODUCTION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
REVIEW OF THE LITERATURE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
Structure and regulation of sleep . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
Association of GH secretion with sleep . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
The effect of injected GH on sleep. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
GH regulatory hypothalamic peptides . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
Somatostatin cells in the CNS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
GHRH cells in the CNS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
Autoregulation of GH-axis in the brain . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
The effect of injected GHRH on sleep . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
The effect of injected somatostatin on sleep . . . . . . . . . . . . . . . . . . . . . . . 10
GH-secretagogues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
The role of galanin as a possible sleep regulating neuropeptide . . . . . . . . 12
AIMS OF THE STUDY. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
MATERIALS AND METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
Experimental animals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
REM sleep deprivation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
Total sleep deprivation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
In situ hybridization protocol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
Cell count and computer densitometry. . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
Analysis of somatostatin cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
Analysis of GHRH cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
Analysis of galanin cells. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
Plasma GH measurement during REM sleep deprivation . . . . . . . . . . . . . 20
Animal surgery for i.c.v. and local microinjections . . . . . . . . . . . . . . . . . . 21
Injection procedure. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
I.c.v. injections of somatostatin and somatostatin antagonist . . . . . . . . . . 22
I.c.v. somatostatin antagonist after REM sleep deprivation. . . . . . . . . . . . 22
I.c.v. injections of galanin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
Microinjections into locus coeruleus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
Sleep polygraphy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
Statistics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
RESULTS . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
The effect of REM and total sleep deprivation on somatostatin mRNA . . 26
The effect of REM and total sleep deprivation on GHRH mRNA . . . . . . 27
The effect of REM and total sleep deprivation on galanin mRNA . . . . . . 28
The effect of REM sleep deprivation on plasma GH . . . . . . . . . . . . . . . . . 29
I.C.V. INJECTIONS OF SOMATOSTATIN, SOMATOSTATIN ANTAGONIST,
AND GALANIN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
Somatostatin and somatostatin antagonist . . . . . . . . . . . . . . . . . . . . . . . . . 30
Somatostatin antagonist after REM sleep deprivation . . . . . . . . . . . . . . . . 31
Galanin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
Microinjections of somatostatin, somatostatin antagonist and galanin into the
locus coeruleus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
GENERAL DISCUSSION. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
THE POSSIBLE ROLE OF GHRH IN THE REGULATION OF SWS. . . . . . . . 34
Paraventricular nucleus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
Arcuate nucleus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
Periventromedial hypothalamic area . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
THE POSSIBLE ROLE OF SOMATOSTATIN IN THE REGULATION OF REM
SLEEP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
Arcuate nucleus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
Periventricular nucleus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
Connections to locus coeruleus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
Injections of somatostatin and somatostatin antagonist . . . . . . . . . . . . . . . 38
CONTRIBUTION OF GALANIN IN SLEEP REGULATION . . . . . . . . . . . . . . 40
CONTRIBUTION OF STRESS IN SLEEP DEPRIVATION EXPERIMENTS . 41
CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
ACKNOWLEDGMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
REFERENCES. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
ABBREVIATIONS
AMP adenosine monophosphate
ANOVA analysis of variance
AUC area under curve
CNS central nervous system
CRH corticotropin-releasing hormone
CSF cerebrospinal fluid
dATP deoxyadenosine triphosphate
EDTA ethylenediaminetetra-acetic acid
EEG electroencephalography
EMG electromyography
EOG electro-oculography
GABA gamma-aminobutyric acid
GH growth hormone
GHRH growth hormone-releasing hormone
GHRP growth hormone-releasing peptide
GHS growth hormone secretagogue
i.c.v. intracerebroventricular
i.p. intraperitoneal
i.v. intravenous
IGF insulin-like growth factor
mRNA messenger ribonucleic acid
NPY neuropeptide Y
p.o. peroral
PBS phosphate-buffered saline
PRL prolactin
REM rapid eye movement
s.c. subcutaneous
SSC saline-sodium citrate
SSR somatostatin receptor
SWS slow wave sleep
TED tris-EDTA-dithiothreitol
tRNA transfer ribonucleic acid
TSH thyroid stimulating hormone
VIP vasoactive intestinal peptide
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INTRODUCTION
The regulatory role of endogenous peptides in the control of sleep and wakefulness was first
indicated by the classical studies in Japan and France at the beginning of this century. It was
observed that cerebro-spinal fluid (CSF) of a sleep deprived dog promoted sleep when injected
intracerebroventricularly (i.c.v.) to a recipient dog (Ishimori 1909, Legendre and PiØron 1910).
A hypothesis was put forward that sleep promoting substances accumulated in CSF during
wakefulness. In further studies it was found that heating or ultrafiltration abolished the observed
sleep promoting effect (Legendre and PiØron 1912), suggesting that the substance was
structurally a thermolabile macromolecule, possibly a peptide.
To date several peptides have been found which affect sleep when injected systemically or
directly into the brain (BorbØly and Tobler 1989). However, administration of pharmacological
doses of a peptide does not necessarily indicate that the peptide has an endogenous function in
the regulation of sleep. In addition it is required that the secretion rhythm of the sleep promoting
substance is associated with the sleep-wake rhythm. Blockade of the action of the endogenous
peptide should also have an opposite effect on sleep, and manipulation of the spontaneous
sleep-wake rhythm e.g. by sleep deprivation should affect the activity of this peptide system.
According to current knowledge there are three putative neuroendocrinological systems which
may be associated with specific vigilance states: association of growth hormone secretion with
slow wave sleep (SWS), the hypothalamo-pituitary-adrenal axis with wakefulness, and the
VIP/prolactin system with REM sleep (Steiger and Holsboer 1997). In addition, there are
several other neuropeptides and macromolecules which affect the structure of sleep, but their
endogenous function in sleep regulation is not completely clear (InouØ and Krueger 1990).
Secretion of GH and the amount of deep SWS decrease similarly during normal aging (Van
Cauter et al. 1998). Decreased SWS may be one contributing factor to poor sleep quality and
increased prevalence of sleep disorders in the elderly. Also in some pathological conditions,
such as fatal familiar insomnia, the deterioration of sleep is coupled with a simultaneous
decrease in GH-secretion (Portaluppi et al. 1995). It is possible that this simultaneous decrease
in both GH secretion and SWS is generated by a common neural mechanism, which may be
related to the GH regulatory neuropeptide system. Better knowledge about this mechanism
could create new strategies for the development of more physiological methods for the
management of poor sleep quality associated with normal aging and pathological conditions.
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REVIEW OF THE LITERATURE
Structure and regulation of sleep
Sleep of terrestrial mammals consists of two main sleep stages: rapid eye movement (REM)
sleep and non-REM sleep which can be further divided into light and deep non-REM sleep.
These stages can be recognized by their typical characters in sleep polygraphy, which includes
electrophysiological recording of brain cortex activity by electroencephalography (EEG), eye
movements by electro-oculography (EOG) and skeletal muscle tonus by electromyography
(EMG). During light non-REM sleep there are typical activity bursts called sleep spindles in
EEG and deep non-REM sleep can be recognized by synchronized EEG activity with high
amplitude and low frequency delta waves, and for this reason deep non-REM sleep is also called
slow wave sleep (SWS). Widely used human sleep stage classification criteria categorizes
non-REM sleep into four stages (S1-4) where S2 is light and S4 deep non-REM sleep. S1
represents transition between wake and light sleep and S3 is an intermediate stage between light
and deep non-REM sleep (Rechtschaffen and Kales 1968). Electrophysiologically REM sleep
differs from non-REM sleep in several ways. During REM sleep, EEG is highly desynchronized
corresponding to the EEG recorded during wakefulness. There is also almost a total loss of
tonus in the skeletal musculature interrupted by occasional twitches especially in the facial
muscles which can be recognized in EMG. In EOG there are bursts of rapid eye movements
which has given the name for this vigilance stage. Because non-REM and REM sleep differ in
several characteristics, these sleep stages can be regarded as two independent vigilance states
together with wakefulness.
According to a current and widely accepted model of sleep regulation, sleeping is controlled
by two separate components: circadian process C which affects the appropriate timing of sleep
and homeostatic process S which accounts for a sufficient amount of sleep (BorbØly 1982). This
is a two process model. The circadian process C is mainly controlled by the rhythmic activity of
the suprachiasmatic nucleus in the hypothalamus. For the homeostatic process S, no single locus
has been found in the CNS. It seems rather to be controlled by several neural systems including
monoamines, neuropeptides, and cytokine transmitters which are localized in the
hypothalamus, basal forebrain and brain stem nuclei (BorbØly and Tobler 1989). There is
another theory, which models the rhythm between REM sleep and the other vigilance states.
According to this reciprocal interaction theory, REM sleep is controlled by feedback regulatory
connections between monoaminergic and cholinergic nuclei in the pontine brainstem (Hobson
et al. 1975). Monoaminergic nuclei of this regulatory system consist of the noradrenergic locus
coeruleus and serotonergic raphe nuclei. These nuclei are most active during wakefulness,
decrease their activity during non-REM sleep and are almost totally inhibited during REM
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sleep. Cholinergic laterodorsal and pedunculo-pontine tegmental nuclei (LDT, PPT) are most
active during REM sleep. Several factors such as neuropeptides may also have modulatory
effects on this REM sleep regulatory system.
Association of GH secretion with sleep
Growth hormone (GH, somatotropin) is a polypeptide hormone consisting of 191 amino
acids in humans and is secreted by somatotropic cells of the anterior pituitary. Unlike the other
pituitary hormones, which affect a specific target organ, GH affects several tissues throughout
the body. The main effects of GH are stimulation of growth in bone metaphyses during growing,
anabolic effect in the muscles, conservation of proteins and carbohydrates, and mobilization of
fat for energy sources (lipolysis). The effects of GH are partly mediated by somatomedins of
which the most important are insulin-like growth factors (IGF) 1 and 2. Although
somatomedins are secreted locally by several tissues, the plasma IGF-1 content is mostly
originated from the liver and kidneys.
Secretion of GH from the anterior pituitary is pulsatile. The secretion bursts are flanked by
almost undetectable levels of plasma GH. GH pulses occur more frequently and the basal level
of plasma GH is higher in females than males who have fewer GH pulses but which are of a
higher amplitude (Van Cauter et al. 1998). In humans there is typically one high secretion pulse
and a few lower ones during the 24-h day-night span (Van Coevorden et al. 1991, Van Cauter et
al. 1998). Soon after the development of radioimmunological hormone assay methods in the
1960s, it was found that the main secretion pulse was closely associated with the beginning of
the sleep phase when the amount of SWS is highest (Takahashi et al. 1968, Honda et al. 1969,
Sassin et al. 1969, Van Cauter et al. 1992). Sampling and measurements of plasma GH at
frequent (up to 30 s) intervals combined with the deconvolution procedure, which
mathematically estimates the rate of secretion of a hormone from the plasma concentrations,
have revealed a close association of GH secretion with SWS phases (Van Cauter et al. 1992,
Holl et al. 1991). Delay, advance or interruption of a sleep phase will shift the main GH
secretion pulse correspondingly (Golstein et al. 1983, Van Cauter et al. 1992). At least in
humans GH secretion is also controlled by an endogenous circadian rhythm. When the sleep
period is shifted from its normal time, some GH is still secreted during the early night according
to the endogenous clock (Van Cauter et al. 1992). GH secretion is highest during growing and
early adulthood. In humans the secretion rate starts to decrease during the fourth decade of life.
During aging the daytime secretion pulses diminish first, while the sleep associated GH pulse
persists longer (Van Cauter et al. 1998).
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In animals it is more difficult to find a correlation between GH secretion and sleep because
many animal species have typically several sleep phases of variable lengths during the 24-h
day-night span. However, elevated plasma GH levels during sleep have been demonstrated in
several mammals (reviewed by Van Cauter et al. 1998). In the rat, which is a widely used animal
model in neuroscience, the GH secretion is pulsatile with an approximately 3-h cycle. This
rhythm is associated with an ultradian sleep-wake rhythm with the same cycle length, so that the
GH pulses precede the sleep maxima by about 24 min (Mitsugi and Kimura 1985). Short term
(3 h) total sleep deprivation during the light phase resulted in a decrease of GH secretion during
the deprivation in the rat (Kimura and Tsai 1984).
The effect of injected GH on sleep
Systemic administration of GH by an intraperitoneal injection has been found to increase
especially REM sleep in cats and rats (Stern et al. 1975, Drucker-Colín et al. 1975). When
endogenous GH was immunoneutralized by an injection of GH antiserum, both SWS and REM
sleep decreased in the rat (ObÆl et al. 1997). In humans, intramuscular bolus injection of GH
before sleep onset was found to increase REM sleep and to decrease SWS (Mendelson et al.
1980). However, a more recent study failed to repeat this finding (Kern et al. 1993).
GH regulatory hypothalamic peptides
Pituitary secretion of GH is controlled by two hypothalamic peptides: growth
hormone-releasing hormone (GHRH) which stimulates GH secretion, and somatostatin
(somatotropin-release inhibiting factor, SRIF) which inhibits it. Somatostatin was isolated and
chemically characterized from the ovine hypothalamus in the early 1970s (Brazeau et al.
1973). Somatostatin is a 14 amino acid cyclic peptide linked by an internal disulfide bridge (Fig.
5). Somatostatin is widely distributed in the body, e.g. in the brain, intestine and pancreas. In
addition to GH secretion, it inhibits the secretion of several other hormones such as TSH,
insulin, glucagon, and also pancreatic secretion. The somatostatin gene is 1.2 kilobases in length
and have one 630 base intron within the coding sequence. Somatostatin mRNA is about 600
base pairs long and codes a 116 amino acid precursor peptide preprosomatostatin (Goodman et
al. 1985). GHRH was isolated and chemically characterized from a pancreatic tumor in a patient
with high GH levels in 1982 (Guillemin et al. 1982). It is a linear peptide containing 43 amino
acids in rats and 44 in humans, but in the blood circulation also shorter forms exist. The rat
GHRH gene spans nearly 10 kilobases in the genome and has five exons which encode a mRNA
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of approximately 700 nucleotides. GHRH mRNA is translated into 104 amino acid precursor
peptide of the rat GHRH (Mayo et al. 1985, Gonzales-Cresbo and Boronat 1991).
Peptide transmitter is synthesized by translation from mRNA in ribosomes and modified
from precursor peptides in the Golgi apparatus. Transmitter peptide is then transported to axon
terminals by axonal transport mechanisms. Except in the case of small molecule transmitters,
there are no re-uptake mechanisms for peptide transmitters in presynaptic terminals and new
transmitter is generated by translation from mRNA (Brownstein 1994). Although translation
and modification of active peptide transmitter from its precursors are regulated by many cellular
mechanisms, the amount of specific transmitter mRNA in a cell can be regarded as a rough
estimate of the synthesis rate of the peptide transmitter. The rate of synthesis is in turn normally
coupled to the release rate of a transmitter and to the activity of a peptidergic neuron.
Somatostatin cells in the CNS
Somatostatin containing neurons are present widely in the CNS, e.g. in many hypothalamic
nuclei, preoptic area, hippocampus and cortex. Somatostatin secreting cells are also found in the
wall of the gastrointestinal tract. The widespread distribution of somatostatin cells in the CNS
strongly suggests that somatostatin may also have functions other than the inhibition of GH
secretion. The somatostatin cells that control GH release are located in the anterior part of the
periventricular nucleus of the hypothalamus (Ishikawa et al. 1987, Merchenthaler et al. 1989),
from where they project to the median eminence. There somatostatin is released to the pituitary
portal vein system from neurosecretory axon terminals and finally to its receptors in the
somatotrophic cells of the pituitary gland (Fig. 1). To date five main types of somatostatin
receptors have been cloned (SSR1-5). Due to alternative mRNA splicing, there are two variants
of SSR2, named SSR2A and B (Florio et al. 1996). All SSRs reduce the production of cyclic
AMP. There are also several other intracellular transduction mechanisms which may couple to
SSRs (Florio et al. 1996). Although all types of SSRs are present in the pituitary, inhibition of
GH secretion is mediated mainly by SSR2 in humans and rats. This action involves inhibition of
cytoplasmic Ca2+ influx. There is a strong expression of SSR1 in the periventricular area and the
median eminence. This receptor type is possibly an auto-receptor in hypophysiotropic
somatostatin cells, where somatostatin reduces its own release by an ultra short-loop feedback
mechanism (Helboe et al. 1998). Somatostatin cells located in the dorsomedial part of the
arcuate nucleus probably inhibit GHRH cells in the same nucleus but do not project into the
median eminence (Willoughby et al. 1989, Merchenthaler et al. 1989) (Fig.1). SSRs are found
in the noradrenergic cells of the locus coeruleus where they inhibit the activity of these neurons
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(Inoue et al. 1988, PØrez et al. 1994, Mounier et al. 1996). The locus coeruleus has projections
to the hypothalamus where noradrenaline stimulates the release of somatostatin in the
periventricular nucleus (Liposits 1993, Mounier et al. 1996). This mechanism may partly
mediate the attenuated GH release during wakefulness when the neurons in the locus coeruleus
are active (Fig. 15).
GHRH cells in the CNS
Unlike somatostatin, the distribution of GHRH neurons in the CNS is restricted to the
hypothalamus (Sawchenko et al. 1985). The most important GHRH cell group controlling the
GH secretion is in the arcuate nucleus (Daikoku et al. 1986) (Fig.1). GHRH containing cells
have also been found in the paraventricular nucleus, dorsomedial nucleus, and in the
periventromedial hypothalamic area (Sawchenko et al. 1985). Hypophysiotropic GHRH cells
in the arcuate nucleus also express tyrosine hydroxylase (TH) and have dopamine as a
co-transmitter. Dopamine is released into the portal circulation of the pituitary, where it
regulates at least the secretion of prolactin and TSH (Niimi et al. 1992). There are possibly
autoregulatory connections within the arcuate GHRH cells (HorvÆth and Palkovits 1988)
(Fig. 1). Two types of GHRH cells exist which have partly different morphology and possibly
also different projections (Daikoku et al. 1986). Most of arcuate GHRH cells project to the
median eminence and are hypophysiotropic, while the GHRH cells outside of the arcuate
nucleus, especially in the periventromedial hypothalamic area project to other hypothalamic
nuclei and neighboring brain areas such as the preoptic hypothalamic area and the basal
forebrain (Sawchenko et al. 1985). These cells may account for the possible neuroregulatory
effects of GHRH. A G-protein mediated receptor for GHRH has been isolated and cloned
(Mayo 1992). In addition to the pituitary gland, the GHRH receptor is expressed in several
hypothalamic nuclei and in the preoptic area (Takahashi et al. 1995).
Autoregulation of GH-axis in the brain
Plasma GH content regulates the activity of hypophysiotropic somatostatin and GHRH cells.
An elevated GH level in plasma increases the synthesis and release of somatostatin and
decreases the synthesis and release of GHRH (Zeitler et al. 1990). Hypophysectomy decreases
the activity of somatostatin cells and increases GHRH cell activity (Minami et al. 1993). GH
receptors are present in periventricular somatostatin cells (Burton et al. 1992). Only a minority
(<10%) of GHRH cells in the arcuate nucleus expresses the GH receptor, which may indicate
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that the effect of GH on GHRH is mediated indirectly by somatostatin, IGFs, or neuropeptide-Y
(NPY) (Burton et al. 1995, Korbonits et al. 1996, Chan et al. 1996). (Fig. 1)
Somatostatin and GHRH cells also affect each other via intrahypothalamic connections
without the involvement of GH (HorvÆth et al. 1989, Zeitler et al. 1991) (Fig.1). Somatostatin
cells in the periventricular nucleus inhibit the activity of GHRH cells in the arcuate nucleus, and
also inhibit the release of GHRH from the axon terminals in the median eminence (Dickson et
al. 1994). Arcuate somatostatin and GHRH cells possibly have a reciprocal regulatory
connection within the nucleus, where somatostatin cells inhibit GHRH cells and GHRH
stimulates somatostatin (HorvÆth et al. 1989). GHRH cells in the arcuate are possibly connected
to the periventricular nucleus where they stimulate cells, but this regulation pathway may be
mediated indirectly by NPY or galanin (Chan et al. 1996) because very few arcuate GHRH cells
have been found to project directly to the periventricular nucleus (Willoughby et al. 1989).
Nevertheless, GHRH fibers and GHRH receptors are present in the periventricular nucleus
(HorvÆth et al. 1989, Takahashi et al. 1995), which suggests that also other than arcuate GHRH
cells may regulate the somatostatin cells in periventricular nucleus.
Feedback regulation by GH and intrahypothalamic connections generate rhythmic alteration
in the expression of mRNA in hypophysiotropic somatostatin and GHRH cells, so that the
maximal mRNA expression in somatostatin cells is 180E out of phase with the maximal
expression of GHRH mRNA (Zeitler et al. 1991). This oscillation may explain the GH secretion
rhythm in rats and GH pulses in humans.
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Fig. 1 Schematic illustration of the hypothalamic regulatory system of the pituitary GH release. SS: somatostatin,
PeV: periventricular nucleus, PaV: paraventricular nucleus.
The effect of injected GHRH on sleep
I.c.v. injection of GHRH increases the amount of SWS, slow wave activity and REM sleep in
rats and rabbits (Ehlers et al. 1986, Nisticò et al. 1987, ObÆl et al. 1988). A similar effect has
also been found after systemic injection of GHRH in rats (ObÆl et al. 1996). The observed
stimulatory effect of systemic GHRH on REM sleep is abolished by hypophysectomy. This
does not affect the SWS promoting effect, which suggests that the effect of GHRH on SWS is
primary and not mediated by GH (ObÆl et al. 1996).
In humans repeated i.v. injections of GHRH have been found to increase the amount of SWS
during the early sleep phase (Steiger et al. 1992, Marshall et al. 1996) or after a single injection
in the middle of the sleep phase after the third REM sleep episode (Kerkhofs et al. 1993). A
single i.v. injection in the early sleep phase increases the amount of REM sleep but has no effect
on SWS (Kerkhofs et al. 1993). Continuous infusion (Sassolas et al. 1986, Kern et al. 1993,
Marshall et al. 1996), bolus injection before or at the sleep onset (Garry et al. 1985, Kupfer et al.
1991) and repeated i.v. boluses during the late sleep phase (Schier et al. 1997) failed to affect the
sleep structure although these treatments increased plasma GH.
Blocking the action of GHRH by i.c.v. injection of a GHRH antagonist (ObÆl et al. 1991) or
antibody (ObÆl et al. 1992) decreased the amount of spontaneous sleep in rats, and
administration of a GHRH antibody also decreased sleep rebound after sleep deprivation. The
amount of GHRH mRNA is highest in the morning when the amount of non-REM sleep is
usually at its highest in rats (Bredow et al. 1996). A GHRH-GH-IGF deficient dwarf mouse
strain has a reduced amount of non-REM sleep (Zhang et al. 1996), which also suggests that
GHRH facilitates non-REM sleep.
The effect of injected somatostatin on sleep
A long term intracerebroventricular (i.c.v.) infusion of somatostatin was found to increase
and depletion of somatostatin stores by cysteamine to decrease REM sleep in rats (Danguir
1986). However, i.c.v. or epicortical administration of a high dose (10Fg) of somatostatin in rats
increased wakefulness during the first two hours after the injection (Havlicek et al. 1976, Rezek
et al. 1976). Intraperitoneal (i.p.) or subcutaneous (s.c.) injection of the long-acting
somatostatin analog octreotide (SMS 201-995, OCT) causes a delayed facilitation of REM
sleep in rats (Danguir and De Saint-Hilaire-Kafi 1988b, Beranek et al. 1997). A selective REM
sleep facilitatory effect has also been found in aged rats after oral or i.p. administration of
octreotide (Danguir 1989). I.p. injection of octreotide counteracts the suppression of REM sleep
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caused pharmacologically by scopolamine (Danguir and De Saint-Hilaire-Kafi 1988b) or by
desipramine (Danguir and De Saint-Hilaire-Kafi 1989). Immunoneutralization of endogenous
somatostatin by i.c.v. infusion of somatostatin antibody decreases REM sleep (Danguir 1988)
and microinjection of somatostatin antibody into the nucleus of the solitary tract antagonizes
carbachol-induced REM sleep in rats (Danguir and De Saint-Hilaire-Kafi 1988a).
Somatostatin appears to stimulate REM sleep in laboratory animals, whereas human studies
have yielded inconsistent results of the effects of somatostatin on sleep. Intravenously (i.v.)
infused somatostatin at the beginning of sleep did not affect the structure of human sleep,
although it suppressed the GH secretion peak (Kupfer et al. 1992). Repeated i.v. boluses of
somatostatin caused only a non-significant tendency of enhanced REM sleep in young males
(Steiger et al. 1992). When somatostatin was injected into elderly subjects according to the
same protocol, REM sleep decreased and the sleep structure deteriorated (Frieboes et al. 1997).
GH-secretagogues
GH-secretagogues (GHS) are a class of synthetic oligopeptides, such as growth
hormone-releasing peptide 6 (GHRP-6), GHRP-2 and non-peptide compounds (MK-677,
L-692,429, L-629,585), which are potent stimulating factors of GH release (Bowers et al. 1984,
Bowers 1994). The GHS receptor, which differs from the GHRH receptor, has been cloned
(Howard et al. 1996) and it is found to be expressed in the pituitary, arcuate nucleus and
ventromedial hypothalamus (Guan et al. 1997). Approximately 25% of the GHRH cells in the
arcuate nucleus and periventromedial hypothalamus express GHS receptor mRNA
(Tannenbaum et al. 1998). GHSs stimulate GH secretion both directly from the pituitary (Cheng
et al. 1993) and indirectly by affecting the activity of GHRH cells in the arcuate nucleus
(Dickson et al. 1995, Dickson and Luckman 1997). The present hypothesis is that the GHS
receptor is a receptor for an unknown endogenous substance controlling GH secretion.
Pharmacological studies of the effects of GHSs on human sleep suggest that these
compounds could facilitate sleep. Repeated i.v. boluses of GHRP-6 during early night increased
the amount of light S2 sleep, although the amount of wakefulness, SWS or REM sleep was not
affected (Frieboes et al. 1995). An i.v. bolus of GHRP-2 after the third REM sleep episode did
not affect sleep parameters significantly while causing a marked GH secretion pulse
(Moreno-Reyes et al. 1998). Oral administration of MK-677 at bedtime for 7-14 days was found
to increase the amount of deep SWS (S4) and REM sleep in young (18-30 years) and REM sleep
in elderly (65-71 years) subjects (Copinschi et al. 1997). GH secretion was not affected while
IGF-1 levels increased as a consequence of GHS treatment in the young subjects. In the old
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subjects administration of MK-766 increased both GH secretion and IGF-1 levels (Copinschi et
al. 1997). The effects of systemic or local injections of GHS on sleep have not been studied in
experimental animals according to the current literature. I.c.v. injection of GHRP-6
paradoxically decreased GH secretion in rats (Yagi et al. 1996). This may be due to stimulation
of hypothalamic somatostatin cells because pretreatment with somatostatin antibody blunted
this effect. I.c.v. injection of GHSs stimulated electrical activity and Fos protein production in
the arcuate GHRH cells in rats (Dickson et al. 1995). Immunoneutralization of endogenous
GHRH strongly decreased the effect of injected GHRP on GH secretion (Yagi et al. 1996),
which suggests that the effect of GHS is mostly mediated by GHRH and not by its direct effect
on somatotrophic cells in the pituitary.
There is a special interest in GHS as a possible remedy against age related attenuation of GH
secretion (Merriam et al. 1997). Spontaneous secretion of GH decreases strongly during the
fourth decade of life and this could partly explain the simultaneous reduction of SWS (Van
Cauter et al. 1998). As presented earlier, many of the known GHSs are effective when
administered orally. Since they stimulate both GHRH and GH secretion they could improve
SWS and REM sleep and also have such beneficial effects as conservation of muscle mass and
decreased accumulation of fat.
The role of galanin as a possible sleep regulating neuropeptide
Galanin is a 29 amino acid peptide isolated first from the porcine intestine (Tatemoto et al.
1983). The human galanin has 30 amino acids. The rat galanin mRNA is about 900 base pairs
and it encodes a 124 amino acid precursor peptide, from which the 29 amino acid galanin is
finally cleaved (Vrontakis et al. 1987). Galanin is present in the gastrointestinal tract and widely
in the CNS where it has been found to participate in many brain functions such as feeding,
memory consolidation, nociception and hormone release (Bartfai et al. 1993). Galanin is
usually co-localized with a non-peptide or with another peptide transmitter: with acetylcholine
in the preoptic area, with GHRH and dopamine in the hypophysiotropic cells of the arcuate
nucleus, with CRH in the paraventricular nucleus, with histamine in the posterior
hypothalamus, and with noradrenaline in the locus coeruleus (Melander et al. 1986, Skofitsch
and Jacobowitz 1985). The post-synaptic effects of galanin are usually inhibitory and mediated
by three types of galanin receptors (Smith et al. 1998). Systemic or intracerebroventricular
injection of galanin increased GH secretion while immunoneutralization or i.c.v. injection of
galanin antagonist decreased it (Bauer et al. 1986, Ottlecz et al. 1988, Gabriel et al. 1993). Since
galanin does not affect GH release from pituitary cells in vitro, it is probable that galanin affects
12
the GH regulatory system in the hypothalamus (Ottlecz et al. 1988). Galanin immunoreactive
fibers are found in the periventricular nucleus (Liposits et al. 1993) and periventricular
somatostatin cells express galanin receptors (Chan et al. 1996). This suggests that galanin
increases GH secretion by inhibiting somatostatin release (Tanoh et al. 1993) (Fig.1). Since
very few GHRH cells in the arcuate nucleus express galanin receptors (subtype 1), it is possible
that GHRH is indirectly involved in this mechanism (Chan et al. 1996).
Since galanin is expressed in brain areas known to regulate vigilance states, e.g. in the
preoptic area, posterior hypothalamus, and locus coeruleus, galanin might directly affect sleep
as a sleep modulatory neuropeptide or by the hypothalamic GH regulatory system. The
noradrenergic locus coeruleus is one possible site for a direct effect of galanin on sleep. Galanin
immunoreactive fibers are found in the locus coeruleus (Skofitsch and Jacobowitz 1985) and
locus coeruleus cells express galanin receptors which inhibit noradrenergic cells like
somatostatin in the same nucleus (Sevcik et al. 1993). Recent findings in human subjects
indicate that i.v. administration of galanin increases sleep (Murck et al. 1999).
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AIMS OF THE STUDY
According to the literature GHRH may act as a slow wave sleep facilitating factor when
injected systemically or i.c.v. Corresponding studies with somatostatin have demonstrated that
somatostatin may facilitate REM sleep, but the results of the studies are divergent showing
some discrepancy between the findings in experimental animals and humans. It should be noted
that the effects of somatostatin receptor antagonist on sleep structure have not been studied.
Further, there is no earlier knowledge about the effects of total sleep deprivation or selective
REM sleep deprivation on the gene expression of GHRH and somatostatin in the hypothalamus.
Furthermore the proposed sleep regulatory role of galanin, which is known to affect the
hypothalamic GH-regulatory system, is almost completely unstudied. For these reasons this
work concentrated on the present series of experiments:
I To measure the effects of selective REM sleep deprivation on somatostatin, GHRH and
galanin mRNA expression in hypothalamic cells, and to measure the effect of recovery
sleep on these neuropeptide mRNAs after REM sleep deprivation.
II To measure the effect of short term total sleep deprivation on somatostatin, GHRH and
galanin mRNA expression in hypothalamic cells, and to compare the differences in the
effects of REM sleep deprivation and total sleep deprivation on the mRNA expression of
these neuropeptides.
III To study the effects of blocking endogenous somatostatin by administering a
somatostatin antagonist on spontaneous sleep and rebound sleep after REM sleep
deprivation, and to compare these effects with those observed after administrations of
somatostatin and galanin.
IV To study the role of the locus coeruleus as one of the possible sites of sleep modulation
by administering somatostatin, somatostatin antagonist and galanin locally into the cells
of locus coeruleus.
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MATERIALS AND METHODS
Experimental animals
Adult male Hannover Wistar (I, II, IV) and Sprague Dawley (III) rats, weight 270-390g, total
number 158 were used. The rats were bred in the colony of the Department of Physiology of the
University of Helsinki (I,II), at the University of Zürich (III) and at the Experimental Animal
Center of the University of Helsinki (IV). The animals were kept in 12/12h light/dark rhythm
with free access to standard rat chow and tap water. The animal experiment protocols and
animal housing conditions were approved by the provincial administrative board in accordance
with the laws of Finland and the European convention for the protection of experimental
animals (N:o 1360/1990).
REM sleep deprivation (I, II, IV)
REM sleep deprivation was achieved by the platform method first described by Jouvet for
cats (Vimont-Vicary et al. 1966) and Morden for rats (Morden et al. 1967). The rats were kept
on small platforms (diameter 6.5- 7.5 cm) surrounded by water of approximately 5 cm depth on
the cage floor. Food and fresh drinking water were freely available during the REM sleep
deprivation. Under these conditions REM sleep is suppressed almost totally (Porkka-Heiskanen
et al. 1995) (IV) because the animal is not able to maintain its balance on the platform during
REM sleep-associated muscle hypotonia. In the in situ histochemistry experiments (I, II) rats
(n=6/group) were deprived in the same waterbath-cage system for 24 h (I, II) or 72 h (II) with
7-9 platforms i.e. the rats were able to move from platform to platform but were unable to sleep
on any of them. The rats in the REM sleep rebound group (n=6) were first deprived for 72 h, and
then they were moved to their usual cage for 24 h. Groups of control animals were kept for
corresponding times on large platforms (diameter 11 cm) which allow the same conditions as
the small platforms otherwise, except that almost the same amount of REM sleep is produced as
in the baseline conditions (Porkka-Heiskanen et al. 1995). An additional control group
consisted of animals housed together and taken directly from their regular cage (home
controls). In plasma GH measurement (II) and i.c.v. injection (IV) experiments deprivation
was produced in single rat cages containing two platforms per rat.
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Total sleep deprivation (III)
Total sleep deprivation was achieved using the gentle handling method (Franken et al.
1993). Rats were kept awake by introducing and removing different objects e.g. pieces of wood
and cardboard boxes from the cage. The aim of this method is to achieve sleep deprivation with
minimal stress by using the natural curiosity of rats i.e. their ability to forget sleeping when they
examine new objects in the cage. The rats were observed continuously, and were woken up by
tapping the cage or by touching them lightly if they were falling asleep regardless of the objects.
Dim red illumination allowed observation during the dark phase. During total sleep deprivation,
the vigilance state was not monitored by on-line EEG, but the criteria for sleep behavior were
identical with those used previously (Tobler and BorbØly 1990, Franken et al. 1993) and sleep
deprivation was produced in the same laboratory (Institute of Pharmacology, University of
Zürich).
In situ hybridization protocol (I-III) (Fig. 2)
At the end of REM (I, II) or total sleep deprivation (III) the rats were decapitated with a
guillotine, their brains immediately removed and frozen on a piece of solid carbon-dioxide. 20
µm coronal sections were cut through the hypothalamus with a cryotome. Sections were
thaw-mounted on gelatin coated slides and stored at -70EC. Before the hybridization the
sections were post-fixed in 4% phosphate-buffered paraformaldehyde (pH 7.4) for 5 min at
+4EC, washed in cold PBS (0.1 M Na2HPO4, 0.15 M NaCl, pH 7.4) for 2 min, acetylated 10 min
in 0.15% triethanolamine containing 2% acetic anhydride, dehydrated with graded ethanols and
delipided for 5 min in chloroform. 48 base oligonucleotide probes were made by
oligonucleotide synthesizer (Northwestern University, Evanston, IL, U.S.A.). The galanin
probe consisted of bases 221-268 of galanin mRNA (Vrontakis et al. 1987), the somatostatin
probe consisted of bases 361-408 of the rat somatostatin mRNA (Goodman et al. 1985), and the
GHRH probe contained the bases 323-370 of the rat GHRH mRNA (Gonzales-Cresbo and
Boronat 1991). The probes were labeled at the 3 end with 35S-dATP (Amersham,
Buckinghamshire, UK) using terminal transferase (TdT, Pharmacia Biotech Europe GmbH).
The purified probe was mixed with 1% yeast tRNA (Boehringer Mannheim GmbH, Germany)
solution and TED (10 mM Tris, 1 mM EDTA, 10 mM dithiotreitol, pH 8.0) buffer, heated to
70EC for 3 min and cooled on ice. The final concentration of the probe in the hybridization
buffer (50% formamide, 10% dextran, 0.3 M NaCl, 10 mM Tris, 1 mM EDTA, 1x Denhardts
and 10 mM dithiotreitol) was 3 pmol/ml, and the specific activity was 3500 Ci/mmol for galanin
(I), 1220-1610 Ci/mmol for somatostatin (II, III) and 1250-1750 Ci/mmol for GHRH (II, III).
16
Sections were covered with 45 µl of hybridization mixture, covered with silanized cover slips
(50x24 mm), and incubated overnight at 37 - 40EC. The slides were washed in 1xSSC (0.15 M
NaCl, 0.015 M sodium citrate, pH 7.0) for 4 x 15 min at 55 EC, followed by 2 x 1 h washes at
room temperature. After dehydration with graded ethanols containing 6% ammonium acetate,
slides were dipped in Kodak NTB-2 emulsion diluted 1:1 with 0.6 M ammonium acetate. The
slides were exposed in light-proof boxes at +4EC for 21 days (galanin), 15-18 days
(somatostatin) and 29-30 days (GHRH). After exposure the emulsion was developed with D-16
developer (+16EC diluted 1:1) and Kodak T-max fixer, and the sections were lightly stained
with cresyl violet acetate for visualization in bright and dark field photo microscopy (Nikon
Labophot, magnification 40 - 400 x). The sections were matched according to the rat brain atlas
of Paxinos and Watson (1986) for analysis. The cells containing mRNA of somatostatin, GHRH
or galanin were identified in the dark field as clusters of bright silver granules around stained
blue nuclei on dark red background. If necessary, the cluster was checked in the bright field as
dark granules around a stained violet nucleus. The specifity of the hybridization was tested by
treatment of the sections with ribonuclease (10 µg/ml, Pharmacia Biotech) and the addition of
100 x the amount of unlabeled probe into the hybridization mixture. Both of these treatments
extinguished the signal in the sections.
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Fig. 2 Schematic presentation of the sequence of the consecutive steps in the in situ hybridization.
Cell count and computer densitometry
The amount of mRNA was measured by counting the number of mRNA expressing cells in
specific nuclei (I-III) or by computer image-analysis densitometry (III). For the cell count, all
cells in the area of the specific nucleus which expressed more than five times the background
granule density were included and counted visually by the microscoper. Both measurements
(cell count and densitometry) were made in 4-6 sections at regular intervals along the
rostrocaudal projection of the studied nucleus and the mean of the measured sections was
calculated.
For the computer densitometry, a Sony CCD video camera mounted in a Nikon Labophot
microscope with a combined dark/light field condenser was used. The video signal was A/D
converted by a LG-3 frame grabber card (Scion Corporation, Frederic, MD, U.S.A.) and image
analysis was done by a NIH Image program running in a Macintosh Centris 650. During the
measurements the analyzer was unaware of the group status of an individual rat. The sections
were analyzed in dark field illumination. The nucleus was encircled by free-hand drawing of a
border around the outermost mRNA-expressing cells in the nucleus. The mean density and the
area of the selection were measured. The mean density of the background was measured from a
rectangular area of corresponding size in the immediate vicinity of the nucleus. The mean
density of the background was subtracted from the mean density of the nucleus and the resulting
difference was multiplied by the area of the nucleus. Multiplication of the signal density with
the area compensates for the influence of the background between the cells to the signal value.
Linearity of the densitometry was tested by regression analysis of measured density values
(n=10) compared with the number of silver granules counted in the same areas. For comparing
the slope of regression values between different sections these measurements were done in four
sections and the slope values were tested by analysis of variance (ANOVA). In the regression
analysis the r2 values were between 0.94 and 0.77 and no significant difference was detected
between the slope values of the different sections (F(3,36)=1.27, P > 0.1).
Analysis of somatostatin cells (II, III)
Expression of somatostatin mRNA was measured in the arcuate and periventricular nuclei of
the hypothalamus. In the arcuate nucleus the somatostatin cells were identified as a densely
packed cell group situated just laterally of the ventral part of the third ventricle (Fig. 3b). In the
REM sleep deprivation study (II) somatostatin mRNA was measured bilaterally from 6 sections
between stereotactical levels -2.1 and -3.6 mm from the bregma. In the total sleep deprivation
study (III) 4 sections were analyzed between -3.1 and -3.5. In the periventricular nucleus the
somatostatin-expressing cells were grouped bilaterally beside the third ventricle (Fig. 3a).
Expression of somatostatin mRNA was analyzed in 4 sections between -1.4 and -1.8.
Analysis of GHRH cells (II, III)
Expression of GHRH mRNA was measured in the paraventricular and the arcuate nuclei. In
the total sleep deprivation study (III) the GHRH cells of the periventromedial hypothalamic area
were also analyzed. The paraventricular nucleus was identified as the area where the GHRH
mRNA- expressing cells were clustered lateral of the third ventricle (Fig. 3a). GHRH cells were
analyzed bilaterally in 4 sections between the levels -1.8 and -2.2 from the bregma. GHRH cells
in the arcuate nucleus were identified as a GHRH mRNA-expressing group of cells situated
ventrolaterally of the third ventricle (Fig. 3b). Analysis was made bilaterally of 6 sections
between the levels -1.9 and -3.4 (REM sleep deprivation) (II) and 4 sections between -3.05 and
-3.45 (total sleep deprivation) (III). GHRH cells in the periventromedial hypothalamic area
were a sparsely distributed group of cells situated dorsolaterally from the arcuate GHRH cells
near the border of the ventromedial hypothalamic nucleus (Fig. 3b). Analysis was made
bilaterally in 4 sections between levels -3.2 and -3.6.
Analysis of galanin cells (I)
Galanin mRNA expressing cells were counted in the medial preoptic area and the
periventricular nucleus in the anterior hypothalamus. In the medial preoptic area galanin
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Fig. 3 Schematic drawing of the rat hypothalamusapproximately from the coronal levels -1.8 (a) and -3.3 (b) from
the bregma. a) locationof somatostatincells in the periventricularnucleus (!) andGHRHcells in the paraventricular
nucleus (#). b) locationof the somatostatincells (!) and theGHRHcells (#) in the arcuatenucleusand theGHRH in
the periventromedial hypothalamic area (*). 3V: third ventricle, F: fornix, ME: median eminence, OT: optic tract,
VMH: ventromedial nucleus.
expressing cells were scattered in the anterior hypothalamus between anterior commissure and
optic chiasm (Fig. 4). Cell counts were made between the stereotactical coronal levels -0.04 and
-1.04 mm from the bregma. Galanin cells in the periventricular nucleus were clustered
bilaterally beside the third ventricle (Fig. 4). Counts were performed in 5 sections between -0.56
and -1.04 mm from the bregma. Cells within a distance of 1 mm lateral from the third ventricle
were included.
Plasma GH measurement during REM sleep deprivation (II)
Rats were provided with a silastic jugular cannula under combined medetomidine
(DomitorR, Orion-yhtymä, Espoo, Finland, 75 µg/kg s.c.) and pentobarbital (MebunatR, Orion,
45mg/kg i.p.) anesthesia. After the operation the cannula was heparinized, and the rats were
allowed 48 h of recovery before the experiment. Five rats were deprived of REM sleep for 24 h
by the platform method. A control group consisted of six rats kept on the large platforms.
During deprivation hours 25-31 samples (200 µl)were collected from the cannula at 20 minute
intervals. Blood was similarly collected from rats (n=4+4) that stayed in their home cages. REM
sleep deprivation and large platform groups were compared to respective home control groups
in two separate radioimmunoassays for GH. In the analysis laboratory the detection limit for
GH-assay was 2.5 ng/ml and the intra- and inter assay coefficient of variations were 4.5% (intra)
and 15.2% (inter) (Laartz et al. 1994). Reagents for the GH assay were provided by the National
Institute of Diabetes, and Digestive and Kidney Diseases (NIDDK, Bethesda, Maryland,
U.S.A.) and RP-2 was used as a GH reference.
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Fig. 4 Schematic drawing of the rat anterior hypothalamus approximately from the coronal level -0.92 from the
bregma. Location of galanin cells in the periventricular nucleus (PE) (!) and in the medial preoptic area (MPA) (#).
F: fornix, OX: optic chiasm, SCN: suprachiasmatic nucleus, 3V: third ventricle.
Animal surgery for i.c.v. and local microinjections (I, IV)
Two dental screw electrodes for electroencephalography (EEG) were implanted into the
scull ipsilaterally above the frontoparietal cortex and two steel wire electrodes for
electromyography (EMG) were inserted into neck muscles under combined medetomidine
(DomitorR, Orion, 0.1 mg/kg s.c.) and pentobarbital (MebunatR, Orion, 30 mg/kg i.p.)
anesthesia. The leads of the electrodes were soldered into a connector, which was secured in
place with dental acrylate. For intracerebroventricular injections (I, IV) a guide cannula (outer
diameter 0.7 mm) was implanted into the lateral ventricle according to stereotactical
coordinates: 0.8 mm posterior from the bregma, 1.4-1.5 mm lateral from the midline, 6.0 mm (I)
or 3.8 mm (IV) ventral from the level of the bregma (Paxinos and Watson 1986). After the
surgery the rats were allowed to recover for 5-7 days before the recordings. After the operation
and during the first post-operative day rats received 20 µg/kg buprenorphine s.c. (TemgesicR,
Reckitt & Colman, Hull, England) for analgesia (IV). During the recovery and experiments the
animals were kept in single animal boxes. Before the experiments the placement of the cannula
was checked by injecting 0.2 µg of angiotensin II (Sigma Chemical Co., St. Louis, MO, U.S.A.
product: A9525) into the cannula. Animals that did not show a clear drinking response were not
used in the experiments. After the experiments the cannula placement was also verified by
microscopy of 20 µm histological cryosections made of the dissected and frozen brains.
Injection procedure (I, IV)
In the i.c.v. experiments a steel injection cannula (outer diameter 0.4 mm) extending 0.5 mm
beyond the guide was used. The cannula was connected by polyethylene tubing to a Hamilton
syringe which was fitted into a CMA/100 microinjection pump (Carnegie Medicin, Stockholm,
Sweden). In the microinjection experiments a cannula made of fused silica capillary
(Composite Metal Services Ltd., The Chase, Hallow, Worcestershire, England.) (outer diameter
0.12 mm, extending 2 mm beyond the guide) was used. The injection system was first filled with
distilled water and then a sufficient amount of injection solution was driven into the tubing
separated from the water by an air bubble. In the i.c.v. injections a 2 µl volume was injected in
4 min (0.5 µl/min) and in the locus coeruleus microinjections 0.25 µl in 5 min (0.05 µl/min).
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I.c.v. injections of somatostatin and somatostatin antagonist (IV)
In the i.c.v. somatostatin antagonist experiment, rats (n=5) received in a random order either
2 µl of artificial cerebrospinal fluid (aCSF) or 0.5 nmol of somatostatin antagonist,
cyclo-(7-aminoheptanoyl-phe-d-trp-lys-thr(bzl)) (Sigma C4801, Fig. 5) dissolved in 2 µl of
artificial CSF or 2 nmol of somatostatin antagonist in the same volume. In the somatostatin
experiment 5 rats received artificial CSF, 0.5 nmol or 2 nmol of somatostatin (Sigma S9129)
according to the same protocol. Injections were given between 9:30 and 10:30 after sleep onset.
I.c.v. somatostatin antagonist after REM sleep deprivation (IV)
24 h REM sleep deprivation was performed by the platform method starting and ending at
9:00 am. After the deprivation, rats were put into their home cages and an injection of artificial
CSF or 0.5 nmol of somatostatin antagonist was given to 4 rats after the onset of sleep. A 2 nmol
dose of somatostatin antagonist was studied using different rats (n=5) with the same protocol.
Every rat received both treatments (artificial CSF and somatostatin antagonist) and there were
3-6 non-experiment days before the same rats were deprived and injected again.
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Fig. 5 Structure of somatostatin,octreotide (synthetic somatostatinanalog) and somatostatinantagonist (SA) used
in this study. Bzl: benzoate.
I.c.v. injections of galanin (I)
In the i.c.v. galanin experiments (I) rats received 0.06, 0.6 or 6 nmol of porcine galanin
(Sigma G5773) at 9:00 am or 0.6 nmol at 8:00 pm (5-6 rats / treatment). Control injections
consisted of saline vehicle. Every rat received altogether 2 treatments (1 dose of galanin and 1
saline control).
Microinjections into locus coeruleus (IV)
In the locus coeruleus microinjection experiments 8 rats received unilaterally 0.25 nmol of
somatostatin, somatostatin antagonist or 0.25 µl of artificial CSF in a random order (Fig. 6).
Injections were given in the morning between 9:30 and 10:00am after sleep onset. Another
group of rats (n=5) received 0.25 nmol of rat galanin (Bachem AG, Bubendorf, Switzerland,
product: H7450) or combined injections of 0.25 nmol of galanin + 0.25 nmol of somatostatin or
0.25 µl of artificial CSF according to the same protocol.
Sleep polygraphy (I, IV)
The EEG and EMG signals were amplified with an 8 channel Beckman type T
electroencephalograph (Offner division, Chicago, U.S.A.). The amplified signal was plotted on
paper (I) or collected and digitized by a CED 1401 plus interface (Cambridge Electronic Design
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Fig. 6 Schematic illustration of the microinjection sites in the brainstem at the coronal level -9.3 - 9.8 from the
Bregma according to photomicroscopic verification.  (right): somatostatin / somatostatin antagonist injections
(n=8), (left): galanin / somatostatin (n=5) (for clarity, plottedon the left side, actual injectionswere performed to the
right). 4V: fourth ventricle, LC: locus coeruleus.
Ltd, Cambridge, England) with a sampling rate of 62 Hz. Data were displayed and stored by a
Spike2 program (Cambridge Electronic Design Ltd) running in a desktop PC. During the
recordings rats were remote-observed by means of a video camera and monitor. Collected data
were categorized visually into wakefulness, non-REM sleep and REM sleep in 30-s epochs
according to the standard criteria (Timo-Iaria et al. 1970). Briefly, wakefulness was defined as
low amplitude and mixed intermediate/high frequencies in EEG and high amplitude EMG with
artifacts caused by body movements. Non-REM sleep was defined as high amplitude slow
waves in the EEG and intermediate EMG amplitude, and REM sleep was defined as
low/intermediate amplitude of predominant theta frequency in EEG combined with low
amplitude EMG with occasional twitches. Transition from non-REM to REM sleep (pre-REM
sleep, high amplitude theta bursts mixed into slow waves in EEG) was allocated equally
between non-REM and REM sleep.
Proportions of vigilance states per 2 h time intervals were calculated from the 6 h (IV) 8 h (I)
recording. In experiment IV the first half hour after the injection was excluded because of the
arousal caused by the injection procedure.
Statistics
The effect of REM sleep deprivation on mRNA expression (I, II) was evaluated with
one-way analysis of variance (ANOVA) between the home cage condition and 24 h or 72 h on
small or large platforms. Significant results were further analyzed by pairwise comparisons
between the treatment groups with Student-Newman-Keuls method (I) or Duncans test (II).
The effects of rebound sleep after 72 h REM sleep deprivation (II) were calculated separately by
two-way ANOVA for the 72 h deprivation and 72 h deprivation + 24 h rebound groups. The
factors were treatment (small or large platform) and length of rebound (0 or 24 h).
The effects of total sleep deprivation on mRNA expression (III) were tested by two-way
ANOVA. The factors were treatment (deprivation or control) and time of decapitation (9:00
after 12 h treatment or 15:00 after 6 h treatment). If interaction between the factors was detected
(P > 0.1 for interaction) all four groups were compared by one-way ANOVA followed with
paired comparisons by Newman-Keuls method.
The plasma GH measurements (II) were evaluated by integrating the area under the curve
(AUC), and the difference between platform and corresponding home cage control groups was
compared using the t-test for independent measurements.
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In the i.c.v. somatostatin, somatostatin antagonist and in the microinjection experiments (IV)
differences in the proportions of the vigilance states between the treatments were compared by
one-way ANOVA for repeated measurements. Significant results were compared pairwise
between the treatments by Newman-Keuls test or by Bonferroni t-test (somatostatin and
somatostatin antagonist microinjections). In the i.c.v. galanin injection (I) and i.c.v.
somatostatin antagonist after REM sleep deprivation (IV) experiments the treatments were
compared by paired t-test. In all statistical tests P < 0.05 was set as a limit of statistical
significance.
25
RESULTS
The effect of REM and total sleep deprivation on somatostatin mRNA
REM sleep deprivation for 24 h increased the number of somatostatin mRNA expressing
cells significantly in the arcuate nucleus when compared to 72 h REM sleep deprivation and
control groups (F(4, 22)=6.72, P = 0.001, Duncan P < 0.05) (II) (Fig. 7a). After 72 h of REM sleep
deprivation there was no difference in the number of somatostatin mRNA expressing cells in the
arcuate nucleus when compared to the corresponding large platform control or home group. In
the periventricular nucleus the number of somatostatin cells was significantly higher after 72 h
of REM sleep deprivation compared to large platform controls (F(4, 18)=3.42, P = 0.03, Duncan
P < 0.05) but neither treatment group differed from the home control group (II) (Fig. 7b). 24 h
REM sleep deprivation did not affect the number of somatostatin mRNA expressing cells in the
periventricular nucleus. After a 24 h recovery after 72 h REM sleep deprivation the number of
somatostatin mRNA expressing cells in the arcuate and periventricular nuclei did not differ
from the control and 72 h deprivation groups (II) (Fig. 7a-b).
Both 6 and 12 h total sleep deprivation increased the amount of somatostatin mRNA in the
arcuate nucleus measured by densitometric analysis when compared to the control groups
(F(1,20)= 5.84, P = 0.03) (III) (Fig. 8a). Cell count showed a similar but non-significant trend
between the deprivation and control groups (F(1,20)= 3.04, P = 0.10). In the periventricular
nucleus, total sleep deprivation did not affect the amount of somatostatin mRNA when
compared to controls (F(1, 20)= 0.01, P = 0.92)(III) (Fig. 8b).
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Fig. 7 The average number of somatostatin (SS) mRNA-expressing cells in the rat arcuate (ARC) (a) and
periventricular (PeN) (b) nuclei. H: home control, S: REM sleep deprivation with the platform method (small
platforms), L: large platform controls. D24 and D72: deprivation for 24 and 72 hours, D72R24: deprivation for 72 h
followed by 24 h of rebound sleep in normal conditions. Vertical bars indicate the standard error of means (SE).
* Duncans test P < 0.05 after one-way ANOVA at significance level P < 0.05.
The effect of REM and total sleep deprivation on GHRH mRNA
REM sleep deprivation for 24 and 72 h on the small platforms decreased the number of
GHRH mRNA expressing cells in the paraventricular nucleus (II) (Fig. 9b). 72 h on the large
platforms also decreased the number of GHRH mRNA cells when compared to home and 24 h
large platform groups (F(4, 19)= 9.01, P = 0.0003, Duncan P < 0.05). In the arcuate nucleus the
number of GHRH mRNA cells tended to be lower in all platform treatment groups when
compared to the home controls. (F(4, 21)= 2.57, P = 0.07) (II) (Fig. 9a). 24h rebound sleep after 72
h deprivation had no effect on the number of GHRH mRNA expressing cells in the
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Fig. 8 Mean optical density of somatostatin (SS) mRNA visualized by in situ hybridization in the arcuate (ARC) (a)
and periventricular (PeN) (b) nuclei. Groups: control (C), sleep deprivation by gentle handling (SD) either for 6 h
during the light phase (decapitated at 15:00) (6 h) or 12 h during the dark phase (decapitated at 9:00) (12 h). * The
amount of somatostatin mRNA increased as a consequence of total sleep deprivation in the arcuate nucleus
(two-way ANOVA: P = 0.03 for SD vs. control).
Fig. 9 The averagenumber of GHRHmRNA-expressingcells in the rat arcuate (ARC) (a) and paraventricular (PaV)
(b) nuclei. H: home control, S: REM sleep deprivation with the platform method (small platforms), L: large platform
controls. D24 and D72: deprivation for 24 and 72 hours, D72R24: deprivation for 72 h followed by 24 h of rebound
sleep in normal conditions. Vertical bars indicate the standard error of means (SE). * Duncans test P < 0.05 after
one-way ANOVA at significance level P < 0.05.
paraventricular or arcuate nuclei when compared to 72 h deprivation or large platform controls
(II) (Fig. 9).
Total sleep deprivation for 6 h during the light phase increased the amount of GHRH mRNA
in the paraventricular nucleus measured by densitometric analysis when compared to controls
and 12 h deprivation during the dark phase (F(3, 20)= 3.57, P = 0.03, Newman-Keuls: P < 0.05)
(III) (Fig. 10a). 12 h total sleep deprivation did not affect the amount of GHRH mRNA when
compared to controls. Cell count from the same areas showed a similar but non-significant
result (F(3, 20)= 1.71, P = 0.20). In the arcuate nucleus 6 or 12 h sleep deprivation did not affect
the amount of GHRH mRNA (F(1,20)=0.43, P=0.52) (III) (Fig.10b). In the periventromedial area
the amount of GHRH mRNA was significantly higher in the morning (9:00am) than in the
afternoon (3:00pm) (F(1,20)= 5.17, P = 0.03) (III) (Fig.10c). 6 or 12 h sleep deprivation did not
have any effect when compared to the control treatments (F(1, 20)= 0.15, P = 0.71). Cell count
showed again a similar but non-significant trend in the difference between 9:00am and 3:00pm
groups in the periventromedial area (F(1, 20)= 3.55, P = 0.07).
The effect of REM and total sleep deprivation on galanin mRNA
After 24 h REM sleep deprivation on the small platforms the number of galanin mRNA
expressing cells increased in the medial preoptic area and the periventricular nucleus when
compared to home and large platform controls (I) (Fig. 11). There was no significant difference
in the number of galanin mRNA expressing cells between the two control groups (home and
large platforms). 6 hour total sleep deprivation during the first half of the light phase and 12 hour
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Fig. 10 Mean optical density of GHRHmRNA visualized by in situ hybridization in the paraventricular (PaV) (a) and
arcuate (ARC) nuclei (b) and in the periventromedial (pVMH) area (c). Groups: control (C), sleep deprivation by
gentle handling (SD) either for 6 h during the light phase (decapitated at 15:00) (6 h) or 12 h during the dark phase
(decapitatedat 9:00) (12 h). * The amount of GHRHmRNA increasedafter 6 h total sleep deprivation in the arcuate
nucleuswhen compared to all other groups (one-wayANOVAP = 0.03,Newman-KeulsP < 0.05) (a). The amount of
GHRH mRNA was higher in the rats decapitated in the morning (9:00) than in the afternoon (15:00) in the
periventromedial area (two-way ANOVA: P = 0.03 for 9:00 (12 h) vs. 15:00 (6 h)) (c).
deprivation during the dark phase did not affect the number of galanin mRNA expressing cells
in the medial preoptic area and the periventricular nucleus (Toppila et al. 1996).
The effect of REM sleep deprivation on plasma GH
Secretion of GH occurred in typical secretion pulses at approximately 3 h intervals. These
pulses were generally much lower in the REM sleep deprived (Fig. 12b) and large platform rats
(data not shown) than in the home controls (Fig. 12a). The plasma GH content approximated by
the integrated area under the curve (AUC) was significantly lower during REM sleep
deprivation (small platforms) and also during large platform treatment when compared to the
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Fig. 11 Number of galanin mRNA-expressing cells in the medial preoptic area (MPA) (a) and in the periventricular
nucleus (PeN) (b) after REM sleep deprivation or control conditions. S: 24 h REM sleep deprivation on small
platforms, L: large platform controls, H: home controls. * one-way ANOVA P < 0.05, Newman-Keuls: S vs. L and H
P < 0.05.
Fig. 12 The effect of REM sleep deprivation on the rat plasma GH profile. (a) untreated animal, (b): REM sleep
deprivationwith the platformmethod. The samples were collected between 24-30 h of REM sleep deprivation. The
amplitude of GH pulses is lower in the REM sleep deprivation animal.
corresponding home control group (small platforms: t(7) = 2.49, P = 0.04, large platforms: t(8)=
2.89, P = 0.02) (II).
I.C.V. INJECTIONS OF SOMATOSTATIN, SOMATOSTATIN ANTAGONIST, AND
GALANIN
Somatostatin and somatostatin antagonist
I.c.v. injection of 0.5 and 2 nmol of somatostatin antagonist reduced the amount of REM
sleep during the post injection period from 0.5-2 hours when compared to artificial CSF controls
(ANOVA: F(2, 8) = 4.66 P < 0.05, Newman-Keuls: P < 0.05) (IV). (Fig. 13a) There was no
difference between the two doses of somatostatin antagonist. Later, during the periods 2-4 and
4-6 hours, there was no significant difference in the amount of REM sleep between the
treatments. Somatostatin antagonist did not affect the amount of non-REM sleep during the 6 h
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Fig. 13 The effect of injected somatostatin (SS) and somatostatin antagonist (SA) on mean proportions of REM
sleep during three post-injection time periods. a: i.c.v. injectionof artificialCSF (aCSF) (vehicle control), SA 0.5 or 2
nmol ( n=5), * F(2, 8)= 4.66,P < 0.05, Newman-Keuls:SA 0.5 and SA 2 vs. aCSFP < 0.05.b: i.c.v. injection of aCSF,
somatostatin 0.5 or 2 nmol (n=5). c: i.c.v. injection of aCSF or 2 nmol of SA after 24h REM sleep deprivation (n=5).
* Paired t-test: t(4)= 4.36, P < 0.05. d: microinjection of aCSF, somatostatin 0.25nmol or SA 0.25nmol (n=8),
* ANOVA F(2, 10) = 8.09, P < 0.01, Bonferronis t-test: SA vs.aCSF t(6)=5.10, P < 0.01. Vertical bars indicate the
standard error of means (SE).
post-injection recording period. I.c.v. injected boluses of corresponding doses of somatostatin
did not affect the amount of REM (Fig. 13b) or non-REM sleep during any post-injection time
period when compared to artificial CSF controls (IV).
Somatostatin antagonist after REM sleep deprivation
After 24 h REM sleep deprivation an i.c.v. injection of 2 nmol of somatostatin antagonist
reduced REM sleep during the time period 2-4 h post injection when compared to artificial CSF
(t(4) = 4.36, P < 0.05) (IV) (Fig. 13c). During the periods 0.5-2 and 4-6 h there was no significant
difference in the amount of REM sleep. Non-REM sleep was not significantly affected. 0.5
nmol of somatostatin antagonist after REM sleep deprivation did not significantly affect the
amount of REM or non-REM sleep during the 6 h recording of recovery sleep when compared
to artificial CSF injection (IV).
Galanin
I.c.v. injection of 0.06, 0.6 or 6 nmol of galanin did not affect the daytime proportions of
REM or non-REM sleep when compared to controls during the 8 h post-injection recording (I)
(Tab. 1). During the first 8 h of the dark phase, when the amount of natural sleep is low in the rat,
0.6 nmol of galanin i.c.v. did neither affect the amount of REM or non-REM sleep when
compared to control injection (I) (Tab. 1).
REM sleep non-REM sleep
% SD % SD
Light
Saline 10.0 1.8 51.9 3.7
Galanin 0.06 9.6 2.0 52.9 7.2
Galanin 0.6 12.8 2.6 48.7 5.0
Galanin 6 12.8 2.4 49.7 7.8
Dark
Saline 5.0 0.5 27.7 2.0
Galanin 0.6 5.0 0.9 21.7 1.9
Tab. 1 The effects of i.c.v. injections of 0.06-6 nmol of galanin on sleep compared to saline controls. Sleep
polygraphy was recorded 8 h during light (started ar 9:00 am) or dark (started at 8:00 pm) phase (lights 8:00 am -
8:00 pm). SD = standard deviation. n = 5-6 per group.
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Microinjections of somatostatin, somatostatin antagonist and galanin into the locus coeruleus
The accepted sites of the microinjection were in the locus coeruleus or in the immediate
vicinity of the nucleus not penetrating the fourth ventricle (Fig. 6). Microinjection of 0.25 nmol
of somatostatin antagonist into the locus coeruleus reduced REM sleep during the post injection
period 0.5-2 hours (ANOVA: F(2, 10)= 8.09, P < 0.01, Bonferroni t(6)= 5.10, P < 0.01) (IV)
(Fig. 13d). Non-REM sleep was not significantly affected. A corresponding dose of
somatostatin did not affect post-injection proportions of sleep phases when compared to
artificial CSF (IV). Microinjection of 0.25 nmol of galanin or a combined injection of 0.25 nmol
of galanin and 0.25 nmol of somatostatin did not affect REM or non-REM sleep during the 6
post-injection hours when compared to artificial CSF injection (IV).
32
DISCUSSION
GENERAL DISCUSSION
According to earlier studies there are several endogenous and synthetic compounds that
affect sleep when injected systemically or directly into the CNS. The sleep modulatory
mechanism of these substances can be either the direct effect on sleep regulatory brain
mechanisms or an indirect effect mediated by e.g. metabolism, thermoregulation or the immune
system. When studying brain mechanisms that regulate sleep, it is important to get knowledge
about not only the sleep modulatory effects of pharmacological manipulation of a neuronal
system, but also about the reciprocal effects of the sleep-wake rhythm and sleep deprivation on
the activity of the studied neuronal system. In the case of the GH-axis and its effects on sleep
there was already established knowledge about the synchronization of GH-secretion and
sleep-wake rhythm, and about the sleep modulatory effects of pharmacological manipulation of
the GH-axis, while the effects of sleep deprivation on the activity on the GH-regulating
neuropeptides in the brain were mostly unknown.
Our results showed that REM sleep deprivation increased somatostatin and decreased
GHRH mRNA in the hypothalamus, while total sleep deprivation (combined lack of slow wave
and REM sleep) increased both GHRH and somatostatin mRNA in the hypothalamus. Earlier
injection studies have revealed that injection of GHRH was capable to induce SWS, suggesting
that GHRH is a possible SWS facilitatory neuropeptide (ObÆl et al. 1996). Our finding that
GHRH mRNA increases during SWS loss but not during REM sleep deprivation when SWS is
possible, is generally in accordance with the findings of the injection studies. According to the
injection studies, somatostatin could facilitate REM sleep but these results obtained from
animal and human studies are not as consistent as the results of the effect of GHRH on SWS.
Our results that the lack of REM sleep achieved either by REM or total sleep deprivation will
lead to increases in somatostatin mRNA in the hypothalamus, and the finding that i.c.v. or local
injection of somatostatin antagonist will reduce REM sleep give further support to the
hypothesis that somatostatin facilitates REM sleep in the brain. We also found that REM sleep
deprivation increases the expression of galanin mRNA in the anterior hypothalamus although
total sleep deprivation did not affect galanin mRNA. I.c.v. or local microinjection of galanin
into the locus coeruleus did not affect the amount of sleep. This may indicate that galanin could
mediate some of the effects of REM sleep deprivation in the brain, but does not itself affect
sleep.
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THE POSSIBLE ROLE OF GHRH IN THE REGULATION OF SWS
The GHRH mRNA expression varied essentially between the hypothalamic GHRH mRNA
expressing nuclei after total or REM sleep deprivation. In the paraventricular nucleus total sleep
deprivation increased while REM sleep deprivation decreased GHRH mRNA. On the other
hand in the arcuate nucleus there were no significant changes after either total or REM sleep
deprivation. In the periventromedial hypothalamic area there was a difference in the amount of
GHRH mRNAs between morning and afternoon samples. It is of interest that sleep deprivation
was ineffective in this respect. Thus it is possible that the GHRH nuclei in the hypothalamus
have partly different functions (Fig. 14). In the following chapters the effects of sleep
deprivation on different GHRH nuclei in the hypothalamus are discussed separately.
Paraventricular nucleus
After 24 h REM sleep deprivation the amount of GHRH mRNA was reduced in the
paraventricular nucleus and this effect was also found after 72 h deprivation. However, at the
72 h time point the amount of GHRH mRNA was similarly decreased in the large platform
controls. This may be due to the possibility that rats staying on the large platforms also
experienced partial reduction of sleep although this was not not found in an earlier study from
our laboratory (Porkka-Heiskanen et al. 1995). The effects of sleep deprivation may occur more
slowly during staying on the large platforms than during staying on the small platforms. In the
latter case 24 h REM sleep deprivation was already enough to reduce the amount of GHRH
mRNA.
Total sleep deprivation for 6 h during the light phase increased the amount of GHRH mRNA
in the paraventricular nucleus, which was an opposite effect to that seen in the REM sleep
deprivation experiment. Total sleep deprivation for 12 hours during the dark phase did not affect
GHRH mRNA in the paraventricular nucleus when compared to controls. The higher effect of
the shorter deprivation may be due to the fact that rats will mostly sleep during the first half of
the light phase, when the 6 h deprivation was performed, and thus more sleep was lost when
compared to situation in the 12 h deprivation during the dark phase, when rats normally are
mostly awake (Franken et al. 1991, Tobler and BorbØly 1990). In a recent study the effects of
total sleep deprivation on GHRH mRNA in the hypothalamus were measured by a reverse
transcription polyclonal chain reaction (RT-PCR) method, and an increase in the GHRH mRNA
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in the whole hypothalamus was observed after 8-12 h total sleep deprivation (Zhang et al.
1998). This finding agrees with our present findings in the specific hypothalamic nucleus.
We found that total sleep deprivation increases, while REM sleep deprivation decreases, the
amount of GHRH mRNA in the paraventricular nucleus. This may be due to the different degree
of sleep deprivation obtained by the total and the REM sleep deprivation methods. During the
total sleep deprivation both non-REM and REM sleep are inhibited, but during REM sleep
deprivation non-REM sleep was reduced only partly. A decrease of 38% in non-REM sleep
during the first 24 h was observed, while REM sleep was inhibited almost totally
(Porkka-Heiskanen et al. 1995). Our finding suggests that total inhibition of non-REM sleep
activates the GHRH cells in the paraventricular nucleus. Reduction of GHRH mRNA in the
paraventricular nucleus during REM sleep deprivation may be due to the inhibition which is
mediated by somatostatin or by other transmitters which mediate the effects of REM sleep
deprivation or stress. Unfortunately the afferent connections of the paraventricular GHRH cells
are poorly known. Nevertheless, it is possible that this subgroup of GHRH cells mediates the
SWS facilitatory effect of GHRH as suggested by the pharmacological studies (Fig. 14). The
paraventricular GHRH cells are hypophysiotropic (Liposits 1993), but the nucleus has also
projections to other brain areas such as preoptic area and basal forebrain (Sawchenko et al.
1985), where cholinergic and GABAergic cells regulate wakefulness and sleep (Szymusiak
1995) (Fig.14). Some cells in the preoptic area express GHRH receptors (Takahashi et al.
1995), but the transmitter identities of these cells are unknown. In a recent study it was found
that local microinjections of GHRH into the preoptic area increased sleep and that
microinjections of GHRH antagonist decreased spontaneous sleep and rebound sleep after short
term sleep deprivation (Zhang et al. 1999). This supports the hypothesis that the preoptic area
may be the target area for the SWS facilitatory effect of the endogenous GHRH.
Arcuate nucleus
In our study neither REM nor total sleep deprivation affected the amount of GHRH mRNA in
the arcuate nucleus. It is known that the arcuate GHRH cells are mostly hypophysiotropic and
that there are very few projections to other areas than the median eminence among these cells
(Merchenthaler et al. 1985). Thus, it is possible that regulation of GH secretion is the main
function of the arcuate GHRH cells and that the mRNA expression of these cells is thus not
particularly sensitive to sleep loss (Fig. 14). Because secretion of GH is reduced during both
REM (II) and total sleep deprivation (Kimura and Tsai 1984), it is probable that the arcuate
GHRH cells are somehow inhibited by hypothalamic somatostatin cells, which increase mRNA
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expression during sleep deprivation. Increased somatostatin activity may reduce the release of
GHRH into the pituitary portal circulation, while the synthesis of GHRH remains unaltered,
which is indicated by the unchanged amount of the arcuate GHRH mRNA after both total and
REM sleep deprivation.
Periventromedial hypothalamic area
In the periventromedial hypothalamic area the amount of GHRH mRNA was higher in the
rats decapitated in the morning (9:00 am) than in the afternoon (3:00 pm), while there was no
difference between the sleep deprivation and control groups. The amount of GHRH mRNA in
the whole of the hypothalamus samples has in another study using Northern blot analysis also
been found to be higher in the morning (Bredow et al. 1996). One possibility is that this
variation of GHRH mRNA may be associated with the daily sleep-wake distribution of the rat.
Rats typically have the highest amount of non-REM sleep during the first half of the light phase
(BorbØly and Neuhaus 1978), at the same time when the amount of the periventromedial GHRH
mRNA was found to be high. The periventromedial GHRH cells are not hypophysiotropic, but
have projections to the preoptic area (Sawchenko et al. 1985), which could mediate the sleep
association of these cells similarly as in the case of the paraventricular GHRH cells (Fig.14).
The afferent connections of the periventromedial GHRH cells are unclear. It is possible, though
at this point only hypothetical, that the activity of these cells is controlled by the
suprachiasmatic or ventromedial nuclei, which activity oscillates in an endogenous circadian
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Fig. 14 Schematic illustrationof the possible roles of the hypothalamicGHRHcell populations.PaV: paraventricular
nucleus, pVMH: periventromedial hypothalamic area.
rhythm. The circadian association of sleep distribution may be partly mediated by this neuronal
pathway.
THE POSSIBLE ROLE OF SOMATOSTATIN IN THE REGULATION OF REM SLEEP
Arcuate nucleus
According to our findings, both 24 h REM sleep deprivation and 6-12 h total sleep
deprivation increased the amount of somatostatin mRNA in the arcuate nucleus. After the
longer 72 h REM sleep deprivation there was no difference in the arcuate somatostatin mRNA
between the REM sleep deprivation and control groups. The observed activation of the arcuate
somatostatin cells as a consequence of REM sleep loss caused by REM or total sleep
deprivation is in accordance with the injection studies suggesting that somatostatin facilitates
REM sleep. It is known that the arcuate somatostatin cells are not hypophysiotropic, but project
locally in the arcuate nucleus where they inhibit the hypophysiotropic GHRH cells
(Merchenthaler et al. 1989, Willoughby et al. 1989). The amount of somatostatin mRNA
oscillates in the arcuate nucleus in association with the GH secretion rhythm (Zeitler et al.
1991). By their effect on the hypophysiotropic GHRH cells in the same nucleus, these
somatostatin cells may mediate the inhibition of GH secretion which is found during REM (II)
and total sleep deprivation (Kimura and Tsai 1984). During the longer REM sleep deprivation
the amount of somatostatin mRNA in the arcuate nucleus returned to the level of the control
group. This may be a consequence of the feedback regulation caused by the decreased plasma
GH, which may inhibit somatostatin cells in the arcuate nucleus.
Periventricular nucleus
In the periventricular nucleus the amount of somatostatin mRNA increased after 72 h REM
sleep deprivation when compared to large platform control treatment but not when compared to
unhandled animals allowed normal sleep. The durations of total sleep deprivation of 6 and 12 h
did not affect the amount of the periventricular somatostatin mRNA. The periventricular
nucleus is the most important source of hypophysiotropic somatostatin by its projection to the
median eminence (Merchenthaler et al. 1989). There are findings that this somatostatin cell
group projects also to other brain areas such as arcuate nucleus and locus coeruleus (Dickson et
al. 1994, Liposits 1993). Because sleep deprivation decreases GH secretion, it would be logical
that the activity of the periventricular somatostatin cells increases during the deprivation. It is
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possible that the transmitter synthesis rate and the stores are so high in this massive somatostatin
cell population that an induction of mRNA expression is not needed during short sleep
deprivation. Another possibility is that these cells regulate primarly GH secretion as do the
GHRH cells in the arcuate nucleus, but that the cells are not sensitive to short sleep deprivation.
Connections to locus coeruleus
Some somatostatin cells in the hypothalamus are connected to cells in the locus coeruleus
(Palkovits et al. 1982, Liposits 1993, Mounier et al. 1996). Somatostatin immunoreactive fibers
have been found in the locus coeruleus (Sutin and Jacobowitz 1988). Expression of
somatostatin receptors SSR1-3 has been observed in this nucleus in various studies (Seæarís et
al. 1994, PØrez et al. 1994, Schindler et al. 1997). Somatostatin affects noradrenergic cells in the
locus coeruleus by decreasing their electrical activity (Inoue et al. 1988). Noradrenergic locus
coeruleus cells have a reciprocal efferent connection to hypothalamic somatostatin cells
(Liposits 1993, Mounier et al. 1996), by which the locus coeruleus stimulates somatostatin
release. Because somatostatin inhibits the locus coeruleus, and inhibition of the locus coeruleus
is needed during REM sleep episodes, it is possible that the locus coeruleus mediates at least
partly the effects of somatostatin on REM sleep (Fig. 15).
Injections of somatostatin and somatostatin antagonist
I.c.v. injection of somatostatin antagonist decreased the amount of spontaneous daytime
REM sleep in rats and also of rebound REM sleep after 24 h REM sleep deprivation. Local
microinjection of somatostatin antagonist into the locus coeruleus decreased the amount of
spontaneous daytime REM sleep. The cells in the locus coeruleus are also capable of mediating
the actions of i.c.v. somatostatin antagonist, because the nucleus is situated in the vicinity of the
fourth ventricle. While somatostatin antagonist was effective, an i.c.v. or locus coeruleus
microinjection of somatostatin did not affect the amount of daytime REM sleep. There are at
least three possible causes which may explain this discrepancy between somatostatin and
somatostatin antagonist. First, the half-life of endogenous somatostatin may be much shorter
than the half-life of synthetic somatostatin antagonist. The fact that in an earlier study (Danguir
1986) an increased amount of REM sleep was found during continuous long-term infusion of
somatostatin supports this hypothesis. However, in another study (Lin et al. 1991) it was found
that the duration of the effect of somatostatin and somatostatin antagonist on the baroreceptor
reflex was almost equal. The second possibility is the ceiling effect. During the first half of the
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light phase, when the amount of sleep is highest in the rats, inhibition of the locus coeruleus
caused by endogenous somatostatin may be strong enough, so that somatostatin injection is
ineffective to cause any further inhibition to increase the amount of REM sleep. In the study of
Danguir (1986), the proportions of sleep phases were calculated in 24 h time periods, which
does not reveal, whether the enhancement of REM sleep was concentrated in the light or dark
phase. The third possibility would be different receptor affinity profiles of somatostatin and
somatostatin antagonist. Periventricular somatostatin cells are autoinhibited through SSR1
receptors, which are located in the pericarya and axon terminals of these cells (Helboe et al.
1998). Due to this autoinhibiton, i.c.v. injection of somatostatin paradoxically increases GH
secretion (Mounier et al. 1996). I.c.v. injected somatostatin inhibits hypophysiotropic
somatostatin release, while the i.c.v. somatostatin is unable to affect somatotropes in the
pituitary directly. Somatostatin terminals in the locus coeruleus may also be autoinhibited by
SSR1 and thus either i.c.v. or local locus coeruleus microinjection of somatostatin may inhibit
the release of endogenous somatostatin, which may blunt the postsynaptic effect of
somatostatin mediated by SSR2 or 3. Somatostatin antagonist may have higher affinity on
postsynaptic somatostatin receptors in the locus coeruleus. It is as well possible that the
somatostatin antagonist which we used has also some antagonist effect on VIP receptors (Chen
et al. 1993). Microinjection of VIP into the oral pontine tegmentum, close to the locus
coeruleus, has been found to increase REM sleep (Bourgin et al. 1999). As mentioned earlier,
i.c.v. injection of somatostatin paradoxically increases GH secretion (Mounier et al. 1996).
According to this, one could expect that the effect of i.c.v. injected somatostatin on REM sleep
is possibly explained by indirect enhancement of GH secretion. However, this hypothesis is not
supported by the finding that i.p. injection of the somatostatin analog octreotide increases REM
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Fig. 15 Schematic illustration of the reciprocal connection between hypothalamic somatostatin cells and
noradrenergic (NA) cells in the locus coeruleus (LC) and the possible connection of somatostatin to the REM sleep
regulatory system in the brainstem (LDT: laterodorsal tegmental nucleus, PPT: pedunculopontine tegmental
nucleus, ACh: acetylcholine).
sleep, while it decreases GH secretion by direct inhibition of pituitary somatotropes (Beranek et
al. 1997). Novel, more potent and specific somatostatin antagonists have been synthesized
(Bass et al. 1996, Hocart et al. 1998), but they are not yet commercially available. These
compounds may reveal the identity of the receptor responsible for the effect somatostatin on
REM sleep.
CONTRIBUTION OF GALANIN IN SLEEP REGULATION
REM sleep deprivation for 24 h increased the amount of galanin mRNA in the
periventricular nucleus and the median preoptic area, while 6 or 12 h total sleep deprivation did
not affect the amount of galanin mRNA in the same regions (Toppila et al. 1996). The galanin
cells in the medial preoptic area, which are sensitive to REM sleep deprivation are intermingled
with or in the immediate vicinity of the GABA and cholinergic cells which regulate cortical and
thalamic activity and the state of vigilance (Szymusiak 1995). Galanin is usually co-expressed
in the cells with another peptide or a non-peptide transmitter (Bartfai et al. 1993). The
co-transmitter identity of the REM sleep deprivation sensitive cells is not clear. I.c.v. injection
of galanin increases GH secretion (Melander et al. 1987), which is possibly mediated by
inhibition of somatostatin cells in the periventricular nucleus, which in turn reverses the
inhibition of GHRH and GH release. This may be one mechanism which could mediate the
hypothetical effects of galanin on sleep. However, we found that i.c.v. injection of galanin at
doses which should affect GH release did not affect day or night-time sleep in the rats. The
periventricular nucleus is connected reciprocally with the locus coeruleus (Liposits 1993),
where galanin receptors in noradrenergic cells decrease the activity of these cells (Seutin et al.
1989). During REM sleep deprivation continuous and/or increased activity of the locus
coeruleus may activate galanin cells in the periventricular nucleus. However, galanin
microinjections into the locus coeruleus did not affect the amount of daytime REM sleep in rats
either alone or when combined with somatostatin. It is possible that these negative findings are
caused by the short half-life of these peptides, or by the ceiling effect during daytime, when the
amount of sleep is high in the rats anyway. However, these findings together with the data of
i.c.v. injections suggests that galanin does not affect sleep when injected i.c.v. or locally into the
locus coeruleus. In a quite recent study a high dose (10 nmol) of galanin i.c.v. decreased
locomotor activity in rats, but the same effect was also obtained by an injection of galanin
antagonist M-35 (Ericsson and Ahlenius 1999). The increased galanin mRNA in the medial
preoptic area and the periventricular nucleus after REM sleep deprivation may mediate the
effects of REM sleep deprivation to other neuronal systems, while it possibly has no direct
feedback connections to sleep regulating systems. Galanin mRNA has been found to increase in
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response to various neuronal stimuli such as lesions and blockade of axonal transport by
colchicine (CortØs et al. 1990a, CortØs et al. 1990b). REM sleep deprivation could be a stimulus
which belongs to this category.
CONTRIBUTION OF STRESS IN SLEEP DEPRIVATION EXPERIMENTS
A certain amount of stress is inevitably associated with any kind of sleep deprivation
procedure. In order to be able to correct for the stress caused during REM sleep deprivation by
the platform method, control groups of rats were kept for the same time on large platforms. It is
suggested that this treatment causes approximately the same amount of immobilization than the
REM sleep deprivation treatment on the small platforms, while REM sleep is not reduced. The
effect of REM sleep deprivation by the platform method on plasma corticosterone has been
measured in our laboratory and there was no significant difference between the REM sleep
deprivation and the large platform control groups during 8-72 h deprivation (Porkka-Heiskanen
et al. 1995). Sleep deprivation by gentle handling has been regarded less stressful than the
platform method and it does not affect blood corticosterone levels significantly (Murison et al.
1982)
Stress activates waking mechanisms in the brain, the same ones which can be assumed to be
activated during sleep deprivation. The noradrenergic locus coeruleus is one important neuronal
system supporting wakefulness and alertness in the brain. Exposure to REM sleep deprivation
but also stress increases the amount of tyrosine hydroxylase mRNA in the locus coeruleus
(Angulo et al. 1991, Porkka-Heiskanen et al. 1995, Basheer et al. 1998). On the contrary, total
sleep deprivation produced by the same protocol as in the somatostatin, GHRH, and galanin
mRNA studies did not affect tyrosine hydroxylase mRNA in the locus coeruleus (Alanko et al.
1996). After stress exposure similar REM sleep rebound in the REM sleep amounts has been
found as after REM sleep deprivation (Rampin et al. 1991). It is well known that all kinds of
stress exposure activate the hypothalamo-pituitary-adrenal axis which leads to increased levels
of glucocorticoids in the plasma by increased release of CRH and ACTH. There is possibly a
similar association between wakefulness and hypothalamic CRH release as between SWS and
GHRH (Steiger and Holsboer 1997, Chang and Opp 1998). I.c.v. injection of CRH increases
wakefulness and decreases SWS, while i.c.v CRH antagonist decreases wakefulness, increases
SWS and has no effect on REM sleep (Ehlers et al. 1986, Chang and Opp 1998).
Stress affects also the GH axis. Acute and repeated stress caused by immobilization increases
somatostatin release in the median eminence (Benyassi et al. 1992, Benyassi et al. 1993) and
decreases plasma GH (Marti et al. 1996, Marti et al. 1993). However, in humans several kinds
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of stressful conditions have been found to increase plasma GH (reviewed by Reichlin 1987).
During acute stress the GHRH release in the median eminence is decreased with a slight delay,
which possibly indicates that this effect is indirect and mediated by somatostatin (Aguila et al.
1991). Sleep deprivation and stressful situations are usually related to increased wakefulness,
when the noradrenergic system in the locus coeruleus is activated (Fig. 15). This may stimulate
hypothalamic somatostatin cells which in turn inhibit GHRH cells in the hypothalamus and GH
release from the pituitary. This hypothesis is supported by the finding that the $-adrenergic
antagonist propranolol reverses the blunted GH response to GHRH caused by glucocorticoid
injections (Devesa et al. 1995). Reciprocally, hypothalamic somatostatin may inhibit
noradrenergic cells in the locus coeruleus by a feedback mechanism, but if the stimulus
supporting wakefulness is strong enough, it will overcome the inhibitory effect of somatostatin,
while the inhibition may make the maintaining of prolonged wakefulness more difficult. When
the stimulus maintaining wakefulness is over, an activated somatostatin system may promote
sleep rebound.
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CONCLUSIONS
I Lack of REM sleep increases somatostatin mRNA and lack of SWS increases GHRH
mRNA in the rat hypothalamus. This together with the earlier pharmacological studies
supports the hypothesis that endogenous somatostatin facilitates REM sleep and GHRH
facilitates SWS.
II Sleep deprivation affects mostly the somatostatin cells in the arcuate nucleus and GHRH
cells in the paraventricular nucleus, which are not the main hypophysiotropic nuclei of
these neuropeptides. Thus, it is possible that sleep regulatory and GH-controlling
functions in the hypothalamus are partly mediated by different somatostatin and GHRH
cell populations.
III REM sleep deprivation increases galanin mRNA in the anterior hypothalamus but
injected galanin does not affect the sleep structure. It is possible that galanin mediates
the effects of REM sleep deprivation in the CNS but does not itself affect sleep via the
areas examined in the present work.
IV Intracerebroventricular and local microinjection of somatostatin antagonist into the
locus coeruleus decreases the amount of REM sleep, which supports the hypothesis that
the effect of somatostatin on REM sleep is at least partly mediated by the locus
coeruleus.
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SUMMARY
The large night-time growth hormone (GH) pulses are associated with slow wave sleep
(SWS) phases in humans and a similar association has been found also in some other
mammalian species. According to previous pharmacological studies an administration of
growth hormone-releasing hormone (GHRH) promotes sleep, especially SWS, in humans and
laboratory animals. Similar studies in rats have shown that somatostatin promotes REM sleep.
The neuropeptide galanin increases GH-secretion and induces sleep in humans. The cells
synthetising GHRH, somatostatin and galanin are mainly located in the hypothalamic areas. In
order to study the possible endogenous role of GHRH, somatostatin and galanin in sleep
regulation we measured the effect of REM and total sleep deprivation on the expression of
mRNA of these neuropeptides in the rat hypothalamus by in situ hybridization. We also
measured the effect of galanin, somatostatin and somatostatin antagonist on sleep by a
polygraphic method in the course of which these peptides were injected
intracerebroventricularly (i.c.v.) or locally into the locus coeruleus of rats. We observed that
selective REM sleep deprivation increased the amount of somatostatin mRNA in the arcuate
nucleus and decreased GHRH mRNA in the paraventricular nucleus. Combined loss of REM
sleep and SWS achieved by total sleep deprivation increased both somatostatin and GHRH
mRNA in these hypothalamic nuclei. Because the paraventricular (GHRH) and arcuate
(somatostatin) nuclei are not the main hypophysiotropic nuclei of GHRH and somatostatin,
control of sleep and wakefulness and GH regulatory functions of these neuropeptides are
presumably performed by different cell populations in the hypothalamus. REM sleep
deprivation increased the amount of galanin mRNA in the hypothalamus, while total sleep
deprivation had no effects. I.c.v. or locus coeruleus microinjections of galanin did not have
effects on sleep. These findings suggest that galanin may mediate some effects of REM sleep
deprivation in the brain, but does not regulate REM sleep by itself. I.c.v. or local injection of
somatostatin did not affect daytime sleep in rats, but a somatostatin antagonist reduced REM
sleep when injected i.c.v. or locally into the locus coeruleus. I.c.v. injection of somatostatin
antagonist also reduced REM sleep when REM sleep propensity was elevated after REM sleep
deprivation. The present findings support the hypothesis that endogenous GHRH promotes
SWS while somatostatin promotes REM sleep. We hypothesize that the locus coeruleus may
partly mediate the effects of somatostatin on REM sleep.
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